Related Experiment Video

Updated: Oct 3, 2026

Multi-system Monitoring for Identification of Seizures, Arrhythmias and Apnea in Conscious Restrained Rabbits
10:25

Multi-system Monitoring for Identification of Seizures, Arrhythmias and Apnea in Conscious Restrained Rabbits

Published on: March 27, 2021

Effect of meropenem on disposition kinetics of valproate and its metabolites in rabbits

K Yokogawa1, S Iwashita, A Kubota

  • 1Department of Hospital Pharmacy, School of Medicine, Kanazawa University, Japan.

Pharmaceutical Research
|October 31, 2001
PubMed
Abstract

Insights

Meropenem significantly increases valproate clearance in rabbits by enhancing renal excretion of valproate-glucuronide and reducing its liver hydrolysis. This impacts valproate drug disposition kinetics.

Area of Science:

  • Pharmacology
  • Drug Metabolism and Pharmacokinetics

Background:

  • Valproate (VPA) is an antiepileptic drug with a complex metabolic pathway.
  • Understanding drug interactions is crucial for safe VPA therapy.

Purpose of the Study:

  • To investigate the effect of meropenem (MEPM) on the disposition kinetics of valproate (VPA) and its metabolites in rabbits.

Main Methods:

  • Rabbits received intravenous valproate (VPA) with or without meropenem (MEPM).
  • Plasma concentrations and urinary excretion of VPA and its metabolites were analyzed.
  • Pharmacokinetic parameters, including clearance and AUC, were calculated.

Main Results:

  • Meropenem significantly increased VPA total plasma clearance by approximately 1.5 times.
  • Meropenem decreased the AUC of 2-en-VPA and VPA-glucuronide (VPA-G).
  • Urinary excretion of VPA-G significantly increased with meropenem co-administration.

Conclusions:

  • Meropenem enhances VPA total clearance, likely due to increased renal clearance of VPA-G.
  • Meropenem may suppress VPA-G hydrolysis in the liver, contributing to altered VPA disposition.

More Related Videos

Microsurgical Skills of Establishing Permanent Jugular Vein Cannulation in Rats for Serial Blood Sampling of Orally Administered Drug08:28

Microsurgical Skills of Establishing Permanent Jugular Vein Cannulation in Rats for Serial Blood Sampling of Orally Administered Drug

Published on: December 14, 2021

Related Concept Videos

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding01:22

Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding

When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .